"Streptococcus pneumoniae" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals.
| Descriptor ID |
D013296
|
| MeSH Number(s) |
B03.353.750.737.872.550 B03.510.400.800.872.550 B03.510.550.737.872.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Streptococcus pneumoniae".
Below are MeSH descriptors whose meaning is more specific than "Streptococcus pneumoniae".
This graph shows the total number of publications written about "Streptococcus pneumoniae" by people in this website by year, and whether "Streptococcus pneumoniae" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Streptococcus pneumoniae" by people in Profiles.
-
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study. Pediatrics. 2023 Jul 01; 152(1).
-
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect Dis. 2023 02; 23(2):233-246.
-
Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine. JAMA Netw Open. 2022 Mar 01; 5(3):e221111.
-
Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr Infect Dis J. 2021 10 01; 40(10):944-951.
-
Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):141-150.
-
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J. 2020 08; 39(8):763-770.
-
Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74?years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2018 01 29; 36(5):606-614.
-
Invasive Pneumococcal Disease Among HIV-Infected and HIV-Uninfected Adults in a Large Integrated Healthcare System. AIDS Patient Care STDS. 2016 10; 30(10):463-470.
-
Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016 08 05; 34(36):4293-7.
-
Passive cigarette smoke exposure and other risk factors for invasive pneumococcal disease in children: a case-control study. Perm J. 2015; 19(1):38-43.